Prescription Justice founder Gabriel Levitt submitted the comments below in response to the FDA’s request for comments on its draft guidance related to “Importation of Certain FDA-Approved Human Prescription Drugs, Including Biological Products, under Section 801(d)(1)(B) of the Federal Food, Drug, and Cosmetic Act: Draft Guidance for Industry.”
Prescription Justice is proud to announce that a statement prepared by PJ President Gabriel Levitt for the U.S. House Ways and Means Committee on “Investing In The U.S. Health System By Lowering Drug Prices, Reducing, Out-of-Pocket Costs and Improving the Medicare Benefit” is now part of the official congressional record.
The New York Daily News recently published the Op-Ed United we stand, at least on drug prices by Prescription Justice President, Gabriel Levitt. Mr. Levitt’s Op-Ed underscores the fact that while there is little consensus among voters from different political parties, there is one stark exception: prescription drug prices.
Today, Prescription Justice announced that it has published a Congressional report card on drug prices. This first of its kind Congressional report card on drug prices can help voters and political organizations determine who they want to support in upcoming elections.
Elizabeth, who is from California, periodically gets migraine headaches. To treat them, she is prescribed brand name Relpax (elitriptan), but finds that the drug is too expensive in the U.S., so she chooses to import the same drug at a much lower price. Despite federal restrictions, most medicines that are imported for personal use reach the patient. But not always. In Elizabeth’s case, instead of receiving her medication, the Food and Drug Administration (FDA) destroyed the medication after it was detained at an international mail facility (IMF). She gave Prescription Justice the green light to tell her story.